Name

Karo Pharma

Legal name

Karo Healthcare AB

Website

https://karopharma.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Consumer Healthcare (OTC)

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacies and Drug Retailers (45611)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

akta.pro secondary industries

Pharmacy & Health Essentials Delivery (CRAFAFAI), Health, Wellness & Pharmacy Online Retailers (CRAFADAG), Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• Consumer healthcare products
• Over-the-counter medicines
• Dermatology skincare brands
• Vitamins mineral supplements
• Intimate digestive health

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Supply Chain, Personnel, Technology or R&D, Operations, Others

Revenue model

1. OTC Consumer Healthcare Products: Sale of branded, original over-the-counter (OTC) products within everyday healthcare categories including skin health, intimate health, digestive health, foot health, and vitamins and mineral supplements.
2. Prescription Medicines: Commercialisation of prescription drugs alongside OTC products, though focus has shifted primarily to consumer healthcare.
3. Digital Commerce and E-commerce: Products sold through digital-first brands on Amazon, e-pharmacies and direct-to-consumer channels through Sylphar platform.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Karo Pharma develops, acquires and commercialises a portfolio of branded, original over-the-counter (OTC) consumer healthcare products and medicines across categories including skin health (E45, Remescar, Decubal, Locobase), intimate health (Multi-Gyn, Pevaryl), digestive health (Proct), foot health (Lamisil), oral health (Flux, Fludent, iWhite), pain relief (Paracet), and vitamins & mineral supplements (Nutravita, Alpha Foods, Lactocare). Products are sold under both legacy Karo brand sites and via in-house e-commerce, distributed across pharmacies, physical retail, and digital channels in 90+ countries with Europe and the Nordic region as core markets.

Product overview

Karo Healthcare operates as a consumer healthcare company with a diversified portfolio of over-the-counter (OTC) medicines, medical devices, and nutritional supplements. The company's product offering consists of multiple acquired consumer health brands organized by therapeutic categories including skin health (E45, Decubal, Apobase, Locobase), foot health (Lamisil, Pevaryl), digestive health (Proct), intimate health (Multi-Gyn), oral care (Flux, Fludent, iWhite), pain relief (Paracet), and vitamins/supplements (Nutravita, Alpha Foods, Lactocare). The portfolio was built through strategic acquisitions, including the Teva portfolio, Sylphar International NV, E45 from Reckitt, and Lamisil from Haleon.

Differentiator

Problem solved

Functional benefit

Brands

• Proct: Digestive Health brand
• Lamisil
• E45
• Nutravita
• Remescar
• Pevaryl
• Flux
• Multi-Gyn
• Paracet
• Alpha Foods
• Decubal
• Locobase

Products and services

• E45 A well-established dermatological skincare brand used for dry skin, eczema, and related skin conditions; sold to consumers across Europe and other markets via pharmacies, retail and e-commerce.
• Lamisil Widely recognised over-the-counter treatment for fungal nail and skin infections, sold to consumers in foot health category across multiple markets.
• Proct Digestive health brand addressing hemorrhoid and anal discomfort treatments for self-care consumers.
• Nutravita Vitamins and mineral supplements brand sold primarily via Amazon, e-pharmacies and other digital channels to consumers across more than 50 countries.
• Multi-Gyn Intimate health brand addressing women's vaginal and intimate care needs with probiotic-based products.
• Pevaryl Antifungal OTC brand for skin and nail conditions, distributed across European markets.
• Remescar Skincare brand offering corrective and instant visible skincare solutions for dermatological needs.
• Flux Oral care brand addressing dental care needs of consumers.
• Paracet Pain relief medication brand for mild to moderate pain, used by consumers across multiple markets.
• Decubal Dermatological skincare brand acquired from Teva, used for dry skin and skin barrier care.
• Alpha Foods Nutritional supplements brand focused on vegan lifestyle and superfood products.
• Locobase Dermatological skincare brand in the Karo Healthcare portfolio, supporting skin barrier care for consumers.
• Satin Naturel Natural cosmetics / aloe vera product portfolio brand acquired through Sylphar.
• MOB-015 (Europe) Exclusive European licence for MOB-015 from Moberg Pharma AB, expanding Karo's portfolio within the dermatology/skin health category.
• Lactocare Probiotic supplement brand acquired as part of the Teva portfolio.
• Apobase Dermatological skincare brand included in the Teva portfolio acquisition.
• Dailycare Personal care brand from the Teva portfolio.
• Fludent Oral care products acquired as part of the Teva portfolio.
• iWhite Teeth whitening brand in the consumer health portfolio.
• E45 brand (Reckitt acquisition) Dermatology brand E45 brought in through the GBP 200m acquisition from Reckitt, supporting the skin health portfolio.
• Sylphar International NV (digital-first platform) Belgium-based digital-first consumer health and beauty platform with brands sold through online marketplaces, web shops and e-pharmacies in more than 50 countries; provides digital commerce capabilities for Karo.

Quantifiable outcome

• Revenue exceeding €500 million
• +2 more outcomes

Named customers2 records

Segments7 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Sylphar NVcoreStrategic or Co-development Partner · 14 August 2026Digital-first platform acquired in January 2022 for EUR 290m, bringing cutting-edge e-commerce and digital marketing capabilities. Sylphar is a Belgium-based fast-growing consumer health and beauty platform with brands sold through online marketplaces, web shops and e-pharmacies in more than 50 countries.
• Moberg PharmacoreOEM/ Whitelabel/ Licensing Partner · 5 November 2025Exclusive license agreement for MOB-015 in Europe, expanding Karo's portfolio within the dermatology/skin health category.
• Operation SmileminorStrategic or Co-development PartnerCharitable partnership supporting Operation Smile since 2018. Every three minutes, a child with cleft lip or palate is born, and Operation Smile performs about 15,000 surgeries per year. Karo supports this initiative as part of its smart choices for everyday healthcare commitment.
• United Nations Global CompactcoreStrategic or Co-development PartnerSignatory since 2022 to the world's largest corporate sustainability initiative.
• Science Based Targets initiative (SBTi)coreStrategic or Co-development PartnerNear-term and net-zero targets validated by the Science Based Targets initiative, supporting Karo's climate ambition aligned with 1.5°C pathway.
• Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development PartnerMember since 2022, promoting responsible supply chain standards and continuous improvement.
• CDP (Carbon Disclosure Project)coreStrategic or Co-development PartnerReports climate performance transparently, achieved B score in 2025.
• Roundtable on Sustainable Palm Oil (RSPO)coreStrategic or Co-development PartnerMember supporting responsible sourcing of palm oil through Certified Sustainable Palm Oil credits.

Scale indicators11 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Stada Arzneimittel: German-based PE-owned (Cinven) pharmaceutical company with significant consumer healthcare and OTC portfolio across Europe, including dermatology, cold/flu and women's health. Direct comparable as a mid-cap European OTC brand aggregator that has executed a similar M&A-driven growth playbook.
• Galderma: Global dermatology-focused pharmaceutical company (owned by Nestlé and EQT) with significant OTC and prescription skin health products. Comparable in skin-health category depth (E45, Lamisil, Decubal, Locobase, Remescar) and similar EQT-private-equity ownership heritage.
• Trimb Healthcare: Swedish-based consumer healthcare company with overlapping Nordic presence and similar OTC brand portfolio focus. Several Karo senior leaders (COO Jonathan Kimber, CSAO Sofia Kyhlstedt) previously worked at Trimb, indicating direct operational and strategic parallels.
• Almirall: Spanish-listed pharmaceutical company with strong dermatology and skin-health OTC focus across Europe. Comparable for portfolio overlap in skin health (E45, Decubal, Locobase, Remescar) and similar Southern European commercial footprint strategy.
• Perrigo Company: US-listed OTC consumer healthcare company focused on store-brand and branded self-care products across skin, digestive, foot health and oral care. Comparable as a similarly diversified European-exposed OTC brand operator competing for the same retailer shelf space and brand divestitures from major pharma.

Broad incumbents

• Haleon: Global OTC consumer healthcare leader (spun off from GSK) owning brands like Voltaren, Centrum, Advil, Sensodyne. Comparable as a major incumbent OTC player from which Karo acquired Lamisil in 2023; overlaps in foot health, oral health, VMS and pain relief categories.
• Bayer Consumer Health: Division of Bayer AG focused on OTC self-care products across categories where Karo competes (digestive health, skin care, foot health). Karo acquired Proctosedyl rights from Bayer in 2024; comparable as a major incumbent divesting non-core OTC assets.
• Reckitt Benckiser: Global consumer healthcare and hygiene major (Dettol, Nurofen, Gaviscon, Durex). Karo acquired E45 from Reckitt in 2022; comparable as a large incumbent divesting non-core consumer health brands that Karo specialises in absorbing and operating at mid-cap scale.
• Nestlé Health Science: Global nutrition, supplements and consumer health business of Nestlé focused on VMS, medical nutrition and preventive health. Comparable for VMS overlap (Nutravita, Alpha Foods, Lactocare) and parent-company dynamics similar to Karo's relationship with major strategic owners.
• Church & Dwight: US-listed consumer products company with growing health and wellness portfolio (Batiste, OxiClean, Trojan, First Response). Comparable as a brand-aggregator consumer health operator with similar multi-category branded portfolio model and disciplined acquisition approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/karo-pharma-ab

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karo Pharma